Screener
Maze Therapeutics MAZE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
FAQ
- What is Maze Therapeutics's cash & equivalents?
- Maze Therapeutics (MAZE) reported cash & equivalents of $202.64M in Q2 2026.
- How has Maze Therapeutics's cash & equivalents changed year-over-year?
- Maze Therapeutics's cash & equivalents decreased by 23.4% year-over-year, from $264.54M to $202.64M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Maze Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude